MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Size: px
Start display at page:

Download "MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents"

Transcription

1 MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015

2 Deficiencies in GDP Phil Neale, GDP Operations Manager Tony Orme, GDP Senior Inspector.

3 Finding deficiencies in GDP is not only for those with magic powers. Deficiencies are just observations of non compliances with GDP and should not be a surprise. Deviations from GDP put patients at risk of poor quality medication 4

4 Major Deficiencies - most commonly reported Temperature control - Environment/Equipment 2. Personnel -Responsible Person duties, training 3. Transportation 4. QMS management documentation 5. Qualification checks Temperature control and monitoring - general 2. Documentation/Procedures 3. Temperature control and monitoring - cold chain 4. Premises and equipment 5. Quality system and duties of RP 5

5 Quality Management System most common deficiency (2015) 1.4 Management review and monitoring Failure to adequately review and incorporate changes driven by regulatory changes or business objectives Failure to assess performance indicators e.g. CAPA, customer complaints. 12

6 QMS Interactive session On your tables with the i-pad spend 10 minutes considering management review and monitoring of the QMS: What makes an effective management review? Who should be included and attend meetings? How frequently should they occur? What topics might be discussed? Are they effective in your own organisation? 14

7 Summary feedback top management be involved, including RP. The agenda should include a review of: internal and external audit findings and reports customer feedback negative and positive supplier performance CAPAs raised or resolved to look for trends in the data process performance is the process reaching/maintaining performance targets? any changes to standards, regulations, technology, competition, staffing, and other business activities that could affect the quality system. Meetings held more frequent than annually 16

8 General QMS deficiencies QMS doesn t reflect the business activities Parts of operation not documented or monitored QMS doesn t reflect GDP or Human Medicines Regulations obligations Deviations / CAPA / Change control poorly managed Management of outsourced activities not controlled 17

9 Quality Management - summary HMR Regulation 43(12) The licence holder must maintain a quality system setting out responsibilities, processes and risk management measures in relation to their activities. Get trained in how to implement a QMS Review the QMS from start to finish against GDP and HMR Ensure all aspects of your operation are controlled Make your QMS work for you and use it effectively Empower staff to report deviations and contribute to CAPAs Regular effective management review of the QMS 18

10 Personnel most common deficiency (2015) Responsible person failing to ensure a quality system is implemented and maintained EU Guidance 2.2 The responsible person should carry out their duties in such a way as to ensure that the wholesale distributor can demonstrate GDP compliance and that public service obligations are met. 21

11 Responsible person Interaction session What can the MHRA and industry do to ensure that this type of deficiency is markedly reduced? On you tables, please discuss and provide some feedback of your ideas on the i-pads (10 minutes) 23

12 The Responsible Person Responsible Persons are appointed based on their knowledge and experience Named on a WDA Is this as far as it goes? Good application of knowledge, experience and common sense to how the Quality System is managed Good communication of knowledge and training Staff involved in operations Take Responsibility for keeping everything up to date and in full compliance 25

13 Premises and Equipment Most common deficiencies Chapter 3 (2015) 3.2 Premises The main deficiencies observed related to the following: Inadequate segregation of medicines of different status Inadequate measures to mitigate against pest infestation. 26

14 Most common deficiencies (2015) Temperature and environment control The main deficiency refers to inadequate temperature mapping: Temperature mapping not adequately recorded (who, what, when, why, how) Temperature mapping not carried out (ambient storage, transport vehicles) Temperature mapping carried out incorrectly, e.g. using a single roaming thermometer to map. 27

15 Equipment Interactive session Domestic refrigerator. Thermometer calibrated at 0, 20 and 40ºC On your tables with the i-pad spend 10 minutes identifying what steps should be taken to demonstrate that the refrigerator is fit for purpose. 29

16 Equipment Validation and qualification reports Risk assessment Design, installation, operation and process qualification Training / SOPs/ maintenance / change control 31

17 Premises and equipment - summary GDP 3.1 Wholesale distributors must have suitable and adequate premises, installations and equipment, so as to ensure proper storage and distribution of medicinal products. In particular, the premises should be clean, dry and maintained within acceptable temperature limits. Equipment calibration Temperature mapping Qualification and validation of key equipment Management of temperature excursions Controlled segregation of medicines of different status A preventative pest control programme 32

18 Documentation Most common deficiencies Chapter 4 (2015) 4.2 Documentation Lack of availability of records Records of purchase and sales are required to be retained for five years (unless longer predicate rules apply). Retention of records applies equally to electronic records even when entered on a spreadsheet. Version control and traceability should be assured and maintained when required by GDP. 33

19 Documentation traceability summary Records must be kept either in the form of purchase/sales invoices, delivery slips, or on computer or any other form, for any transaction in medicinal products received, supplied or brokered. Records should be made at the time each operation is undertaken. 34

20 Qualification checks on Customers -Most common deficiencies (2015) Failure to demonstrate that customer status was re-assessed routinely Failure to obtain notarised translations of authorisations for non UK customers Failure to demonstrate that customers in third countries were authorised to import into that country the specific medicines supplied. 35

21 Qualification checks Chapter 5 - some real examples 1. Botox supplied to an unlicensed dentist and then sold to physicians in USA 2. GSL Products purchased by large wholesaler from unlicensed company 3. POM products sold to Hong Kong doctors. No documentation available authenticating customers 4. Purchases from a Turkish company with no evidence that the company was authorised in Turkey 36

22 Qualification checks more real examples 1. No notarised translation process in place for authorisation documents for non-english suppliers and customers 2. Obtained a copy of the licence but did not accurately check the authorised activities matched the trade e.g. buying cold chain from someone who is not licensed to do it etc. 3. Not checking that both the physical location of supply and the payee are both authorised 4. Large company unable to buy a product directly from manufacturer, decided to purchase from a sole trader, who was unlicensed and the product had been stolen 37

23 Qualification checks Interaction session Qualification checks on suppliers and customers requirements described in EU Guidance are a cornerstone in the protection of public health Why is it difficult for companies to meet requirements on Qualification checks? What can be done to reduce deficiencies? On your tables, please discuss and provide ideas as feedback on the i-pads. ( 10 minutes) 39

24 Transportation the hidden and sometimes unknown process 41

25 Most common Transport Deficiencies Transportation is outsourced and little is known about it Lack of appropriate oversight of transportation and knowledge of specific journeys. EU Guidance Transport (Chapter 9) Transportation providers should be made aware by the wholesale distributor of the relevant transport conditions applicable to the consignment Risk assessment of delivery routes should be used to determine where temperature controls are required. 42

26 Most common deficiencies (2) Transport storage space temperature variations not known Inadequate monitoring or assessment of temperature during transport EU Guidance ( Chapter 9) It is the responsibility of the wholesale distributor to ensure that vehicles and equipment used to distribute, store or handle medicinal products are suitable for their use and appropriately equipped to prevent exposure of products to conditions that could affect their quality and packaging integrity. The required storage conditions for medicinal products should be maintained during transportation within the defined limits as described by the manufacturers or on the outer packaging. 43

27 Transport risk assessment Credit: Maersk Line 44

28 Transport Risk assessment 45

29 Transportation - summary Transportation is outsourced and little is known about it Reliance on the customer who collects Lack of appropriate oversight of transportation and knowledge of specific journeys. Inadequate monitoring or assessment of temperature during transport Transport storage space temperature variations not understood Absent or poor risk management of processes and journeys made in getting product to the customer 46

30 Transportation-Interaction session Why are these transportation deficiencies so common and frequent, when EU Guidance is very clear as to what the responsibilities are? What can industry and the MHRA do to reduce the number of transportation deficiencies? On your tables, please discuss and provide ideas as feedback on the ipads. (10 minutes) 48

31 How can we all improve? MHRA On- site discussions and inspection follow up GDP Symposium Green Guide Gov.uk website Inspector Blogs E-Learning packages Pharmaceutical Wholesalers RP Given time and authority Improved attention to details Harmonise processes for checks Use temperature control approved hauliers All agreements in place and understood 51

32 Questions and contact 52

33 Crown copyright 2015 About copyright All material created by the MHRA, including materials featured within these MHRA presentation notes and delegate pack, is subject to Crown copyright protection. We control the copyright to our work (which includes all information, database rights, logos and visual images), under a delegation of authority from the Controller of Her Majesty s Stationery Office (HMSO). The MHRA authorises you to make one free copy, by downloading to printer or to electronic, magnetic or optical storage media, of these presentations for the purposes of private research, study and reference. Any other copy or use of Crown copyright materials featured on this site, in any form or medium is subject to the prior approval of the MHRA. Further information, including an application form for requests to reproduce our material can be found at Material from other organisations The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned. 53

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Complex Business Models - Outsourced Activities Presented by: Jacqueline Masayi, GDP Inspector Background Increased complexities of the

More information

Building Quality Metrics. Mark Birse, Deputy Director & Head of Inspectorate

Building Quality Metrics. Mark Birse, Deputy Director & Head of Inspectorate Building Quality Metrics Mark Birse, Deputy Director & Head of Inspectorate Indicators of mature Quality Culture: Led from the top, empowered from below Communication of priorities To personnel To shareholders

More information

Wholesaling & Distribution & the GMPs

Wholesaling & Distribution & the GMPs Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the

More information

Wholesaling & Distribution & the GMPs

Wholesaling & Distribution & the GMPs Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the

More information

Good Documentation Practice Session 2

Good Documentation Practice Session 2 Good Documentation Practice Session 2 Good Documentation Practice A refresher EU GMP Chapter 4: Documentation Required GMP documentation: Site Master File Instructions: Specifications Manufacturing Formulae,

More information

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Enforcement activities - Impact of the falsified medicines directive Presented by: Peter Blundell, GDP Inspector Impact of the falsified

More information

Good Documentation Practices. Documentation Requirements For Regulated Environments

Good Documentation Practices. Documentation Requirements For Regulated Environments Good Documentation Practices Documentation Requirements For Regulated Environments Agenda Example Deficiency 2014 Result Of Poor Record Creation Data Integrity EU GMP Chapter 4 Requirements Non GMP Compliant

More information

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we

More information

New GDP Guidelines - Implementation

New GDP Guidelines - Implementation New GDP Guidelines - Implementation Alfred Hunt, Inspector Wholesale Distribution Conference 11 th November 2014 New GDP Guidelines 2013/C 63/01-8 th September 2013 2013/C 343/01-5 th November 2013 2 1994

More information

Feedback from Inspection Programme

Feedback from Inspection Programme Feedback from Inspection Programme Wholesale Distribution Conference 8 th February 2017 Darren Scully Health Products Distribution Manager Wholesale distribution overview wholesale distribution procure

More information

Implementation of EU Falsified Medicines Directive

Implementation of EU Falsified Medicines Directive Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views

More information

Qualification and validation: - an inspector s perspective. Ian Rees, Unit Manager Inspectorate Strategy

Qualification and validation: - an inspector s perspective. Ian Rees, Unit Manager Inspectorate Strategy Qualification and validation: - an inspector s perspective Ian Rees, Unit Manager Inspectorate Strategy GMP - basics A system within an organisation (or linked organisations) to assure the quality of its

More information

Healthcare Good Distribution Practice (GDP)

Healthcare Good Distribution Practice (GDP) Healthcare Good Distribution Practice (GDP) 10 March 2018 Copyright silverbacklogistics.com. All rights reserved The place to go for free supply chain advice 1 The role of the MHRA Ensuring that medicines

More information

Inspection findings on Health Based Exposure Limits and Cross Contamination. Graeme McKilligan, UK, MHRA.

Inspection findings on Health Based Exposure Limits and Cross Contamination. Graeme McKilligan, UK, MHRA. Inspection findings on Health Based Exposure Limits and Cross Contamination Graeme McKilligan, UK, MHRA. Content Some Metrics Key issues encountered Examples of deficiencies Key challenges for inspectors

More information

GDP Audits : Weak points when conducting GDP Audit based on inspections

GDP Audits : Weak points when conducting GDP Audit based on inspections GDP Audits : Weak points when conducting GDP Audit based on inspections s COOL SUPPLY System & Solutions 2017 Webinar 15 February 2017 Riekert Bruinink Dutch Healthcare Inspectorate 2 Titel van presentatie

More information

Management System Hilton Olympia, London 13 th February 2013

Management System Hilton Olympia, London 13 th February 2013 14. Building A Robust Quality Management System Hilton Olympia, London 13 th February 2013 Calcott Consulting consultant to the pharmaceutical & biotechnology industry Presenter s note Please note, the

More information

MINISTRY OF HEALTH ORDINANCE

MINISTRY OF HEALTH ORDINANCE MINISTRY OF HEALTH 1800 Pursuant to Article 114, paragraph 2, Article 120, paragraph 3 and Article 127 of the Medicinal Products Act (Official Gazette 76/2013), the Minister of Health hereby issues the

More information

Good Distribution Practices Toolkit. Quality Management System 08 March 2016

Good Distribution Practices Toolkit. Quality Management System 08 March 2016 Good Distribution Practices Toolkit Quality Management System 08 March 2016 1 Quality Policy GDP, Legal, Environmental, H&S Processes & Systems Resources Risk Assessments 2 Quality Policy & Objectives

More information

Overview SFLGDP1. Develop, implement and maintain a quality system to control the distribution of medicinal products

Overview SFLGDP1. Develop, implement and maintain a quality system to control the distribution of medicinal products Overview This standard is about developing, implementing and maintaining a quality system to control the. You will be responsible for developing the quality system and confirming colleagues understand

More information

Guide to Good Distribution Practice of Medicinal Products for Human Use

Guide to Good Distribution Practice of Medicinal Products for Human Use Guide to Good Distribution Practice of Medicinal Products for Human Use IA-G0046-3 9 NOVEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes

More information

Guidelines on Good Distribution Practice of Medicinal Products for Human Use. CF edition

Guidelines on Good Distribution Practice of Medicinal Products for Human Use. CF edition Introduction Introduction These guidelines have been prepared in accordance with Article 10 of Council The present guidelines are based on Articles 84 and 85a(3) of Directive Directive 92/25/EEC of 31

More information

Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use

Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/an D(2010) 380358 Commission Guidelines on Good Distribution Practice

More information

Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation

Third Stakeholders forum on the implementation of the new Pharmacovigilance legislation Safeguarding public health Third Stakeholders forum on the implementation of the new Pharmacovigilance Pharmacovigilance system master file an approach towards system simplification Joanna Harper Inspections,

More information

European Medicines Agency Inspections

European Medicines Agency Inspections European Medicines Agency Inspections London, 14 July 2008 Doc. Ref. EMEA/INS/GMP/361819/2008 COMMUNITY PROJECT ON THE PRACTICAL IMPLEMENTATION OF THE NEW OBLIGATIONS FOR MANUFACTURING AUTHORISATION HOLDERS

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL Licence to act as a Wholesaler or Distributor MEDICINES CONTROL COUNCIL GUIDELINES FOR LICENCE TO ACT AS A WHOLESALER or DISTRIBUTOR This guideline is intended to provide recommendations to applicants

More information

Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland

Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland IA-G0008-5 17 JUNE 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance

More information

Early Access to Medicines Scheme (EAMS)

Early Access to Medicines Scheme (EAMS) Early Access to Medicines Scheme (EAMS) Safe and Timely Access to Medicines for Patients (STAMP) Dr Daniel O Connor May 2015 Expert Medical Assessor MHRA Early Access to Medicines A proposal for an Early

More information

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil

More information

Overview sulla nuova guideline GDP

Overview sulla nuova guideline GDP AFTI 09 febbraio 2012 Overview sulla nuova guideline GDP Fabio Dotto Ispettorato Regionale Medicamenti Svizzera del Sud 1 113 GDP Guidelines GDP of Medicinal Products for Human Use Public consultation

More information

Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation

Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation Module II - Pharmacovigilance system master file Presented by: Joanna Harper Inspections, Enforcement & Standards

More information

Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES

Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES DB Schenker Healthcare Conference Europe April 17-18 th 2012 J. BERLO Industrial Pharmacist/Clin. Biol.

More information

Review of HPRA Draft Guide to Distribution of Medical Devices, including in vitro diagnostic Medical Devices

Review of HPRA Draft Guide to Distribution of Medical Devices, including in vitro diagnostic Medical Devices Review of HPRA Draft Guide to Distribution of Medical Devices, including in vitro diagnostic Medical Devices Ref: IA-G0004-x Summary DCC Vital welcomes the new draft guidance which will provide clarity

More information

Pharmacovigilance Inspection Metrics Report

Pharmacovigilance Inspection Metrics Report Pharmacovigilance Inspection Metrics Report April 2016 - March 2017 1. Introduction During the period 01 April 2016 to 31 March 2017, the GPvP Inspectorate conducted 36 inspections of marketing authorisation

More information

Guide to Quality System for General Sale Wholesale Distributors

Guide to Quality System for General Sale Wholesale Distributors Guide to Quality System for General Sale Wholesale Distributors IA-G0038-5 20 DECEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

ECMC Annual Network meeting

ECMC Annual Network meeting ECMC Annual Network meeting May 2017 Dr Kirsty Wydenbach Senior Clinical Assessor / CTU Deputy Unit Manager MHRA approach to assessing early phase cancer study protocols 2 in prinicpal no different to

More information

GMP Inspection Deficiencies Review of Deficiencies Observed in 2013.

GMP Inspection Deficiencies Review of Deficiencies Observed in 2013. GMP Inspection Deficiencies 2013 Review of Deficiencies Observed in 2013. Executive Summary The most frequently encountered defect categories raised over the previous five years have remained relatively

More information

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September

More information

Inspection of API Manufacturers & Update on Registration Process

Inspection of API Manufacturers & Update on Registration Process Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers

More information

The challenges of software medical device regulation.

The challenges of software medical device regulation. The challenges of software medical device regulation. david.grainger@mhra.gov.uk Introduction A brief history of software device regulation A look at the new device regulations 2 Current framework In Vitro

More information

Overview SFLGDP1- HP Develop, implement and maintain a quality system to control the distribution of medicinal products

Overview SFLGDP1- HP Develop, implement and maintain a quality system to control the distribution of medicinal products - HP97 04 Overview What this standard is about This standard is about developing, implementing and maintaining a quality system to control the. You will be responsible for developing the quality system

More information

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1 Quality Risk Management of the GDP Supply Chain Crowne Plaza Hotel, 25/2/2010 Dr Cormac Dalton Inspector Date 22-Feb-10 Slide 1 Supply Chain Experiment Pharmaceutical excipient ordered 3 rd December 09

More information

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016

New GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016 New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised

More information

c) Have personnel been appointed to supervise the production operations across all shifts in order to ensure the product quality?

c) Have personnel been appointed to supervise the production operations across all shifts in order to ensure the product quality? Factory s Quality Assurance Ability 1 Responsibilities and Resources 1.1 Responsibilities a) Have the responsibilities and interrelation of various personnel involved in quality activities been defined?

More information

Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products

Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products March 2014 Table of Content INTRODUCTION 3 Section 1: GENERAL RESPONSIBILITIES OF HOLDER

More information

QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain

QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain Presented by: Karen Ginsbury For IFF 01 March, 2017 Pharma Supply Chain Manufacturer Wholesaler Raw Material Supply Production Transport Warehouse

More information

Competence in Clinical Trials the Regulators Perspective.. (Jennifer Martin Senior GCP Inspector, 9 June 2014)

Competence in Clinical Trials the Regulators Perspective.. (Jennifer Martin Senior GCP Inspector, 9 June 2014) Competence in Clinical Trials the Regulators Perspective. (Jennifer Martin Senior GCP Inspector, 9 June 2014) Requirements Statutory Instrument 2004/1031 (as amended) Regulation 28(2): The sponsor (and

More information

Deficiencies found in Inspections and QP Responsibilities

Deficiencies found in Inspections and QP Responsibilities Deficiencies found in Inspections and QP Responsibilities Ciara Turley, HPRA Inspector QP Forum, Trinity College, Dublin 25 th April 2017 Dublin Key QP Responsibilities Chapter 1, 1.4 (xv) Medicinal products

More information

Outsourcing - managing risks and opportunities over which you now have less control

Outsourcing - managing risks and opportunities over which you now have less control Outsourcing - managing risks and opportunities over which you now have less control Kevin O Donnell, PhD PDA Meeting, Dublin 22 nd November 2018 Slide 2 Typical Examples The key GMP Requirements & Guidance

More information

Maritime and Coastguard Agency LogMARINE GUIDANCE NOTE

Maritime and Coastguard Agency LogMARINE GUIDANCE NOTE Maritime and Coastguard Agency LogMARINE GUIDANCE NOTE MGN 524 (M+F) Life-Saving Appliances - Category C Medical Kits - Wholesale Distribution Authorisation - Wholesale Dealers Licence Notice to all :-

More information

Quality Risk Management

Quality Risk Management Safeguarding public health Quality Risk Management Challenges and opportunities Ian Thrussell Strategy and Development Team GMP Inspection, I&S Division Ian.Thrussell@mhra.gsi.gov.uk Presentation overview

More information

Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot

Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot World Stem Cells & Regenerative Medicine 2014 Dr Daniel O Connor Disclaimer The views expressed do not necessarily

More information

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008

Qualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008 Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...

More information

Guide for Distributors of Medical Devices

Guide for Distributors of Medical Devices Guide for Distributors of Medical Devices IA-G0004-1 8 FEBRUARY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 SCOPE 3

More information

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017 Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical

More information

List of deficiencies arising from blood bank inspections classified as major

List of deficiencies arising from blood bank inspections classified as major List of deficiencies arising from blood bank inspections classified as major The average over the 27 sites is approximately 2.1 major deficiencies per site. The minimum major deficiency per inspection

More information

QUALITY SYSTEM MANUAL

QUALITY SYSTEM MANUAL TITLE: QUALITY SYSTEM MANUAL Page 1 of 15 QUALITY SYSTEM MANUAL TITLE: QUALITY SYSTEM MANUAL Page 2 of 15 Index PARAGRAPH TITLE... PAGE 1.0 GENERAL INFORMATION... 3 2.0 DEFINITIONS... 5 3.0 RELATED DOCUMENTS...

More information

Comparability: Regulatory Perspective

Comparability: Regulatory Perspective Comparability: Regulatory Perspective Louise Bisset PhD Pharmaceutical Assessor Biological Medicinal Products (Drug Product Licensing) PSCP workshop 14-15 th Sept 2015, Cambridge. Outline Introduction

More information

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager

Evaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager Evaluation of Counterfeit Cases Impact of FMD & GDPs Wholesale Distribution Information Day, 28th September 2012 Lorraine Nolan Healthcare Products Distribution Manager Slide 1 Contents 1. Review of UK

More information

GMP Track 1 Day 2 Session 1 Vendor Assurance

GMP Track 1 Day 2 Session 1 Vendor Assurance GMP Track 1 Day 2 Session 1 Vendor Assurance 11 August 2015 150403_POUT This session Three presentations Chapter 6 and 7 - Trevor Schoerie Quality Control Out sourced Activities Draft - FDA Quality Metrics

More information

Guidance on the interpretation and implementation of European Good Distribution Practice Chapter 2 Personnel

Guidance on the interpretation and implementation of European Good Distribution Practice Chapter 2 Personnel Guidance on the interpretation and implementation of European Good Distribution Practice Chapter 2 Personnel A joint publication of the European Compliance Academy and the Pharmaceutical Quality Group

More information

Page 1 / 11. Version 0 June 2014

Page 1 / 11. Version 0 June 2014 Page 1 / 11 CORRESPONDENCE MATRIX NQSA NSQ-100 version 0 NUCLEAR SAFETY AND QUALITY MANAGEMENT SYSTEM REQUIREMENTS Model for quality management in design & development, manufacturing, erection, commissioning

More information

Document 2007 Rev 0 December 2005 Page 1 of 8

Document 2007 Rev 0 December 2005 Page 1 of 8 Document 2007 Rev 0 December 2005 Page 1 of 8 1. Scope... 2 2. Definitions... 2 a. LabTest...2 b. Factory Location/ Manufacturer's Premises...2 c. Manufacturer...2 d. Subcontractor...2 e. f. Out-Worker...2

More information

CMI Guidance Document

CMI Guidance Document CMI Guidance Document for Product Quality Plan Requirements Reference CMI-GD-PQP This document has been produced by the Administration Department of CertMark International (CMI). For technical information

More information

GAMP5 Validation for Dynamics 365

GAMP5 Validation for Dynamics 365 GAMP5 Validation for Dynamics 365 Prepared by: Michael Webster, Business Development Director, RSM US LLP michael.webster@rsmus.com, +1 617 241 1544 Dynamics 365 is an ideal enterprise resource planning

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

Section 3 Company Organisation and Certification Procedures

Section 3 Company Organisation and Certification Procedures OF&G ORGANIC STANDARDS AND CERTIFICATION MANUAL 3.0 Contents Page The describe how the company is structured and administered, and explains the certification procedures, the complaints procedures and the

More information

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency

Stakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency New Pharmacovigilance Legislation and Implementing Measures Minimum Requirements for Quality Systems (MAH, EMA, NCA), minimum requirements for Pharmacovigilance System Master File Stakeholder Meeting,

More information

IBS Electronics, Inc.

IBS Electronics, Inc. ******************************* *** Quality Policy Manual ISO9001:2015 Uncontrolled When Printed 3506-D W. Lake Center Dr. Santa Ana, Ca 92704 U.S.A. 714.751.6633 800.527.2888 714.751.8159 FAX. E-mail:

More information

Computerised Systems. Alfred Hunt Inspector. Wholesale Distribution Information Day, 28 th September Date Insert on Master Slide.

Computerised Systems. Alfred Hunt Inspector. Wholesale Distribution Information Day, 28 th September Date Insert on Master Slide. Computerised Systems Wholesale Distribution Information Day, Alfred Hunt Inspector Date Insert on Master Slide Slide 1 Index What is a computerised system Updates to EU GDPs Expectations Case studies Slide

More information

Frequently Asked Questions Secondary care services and the Falsified Medicines Directive (FMD)

Frequently Asked Questions Secondary care services and the Falsified Medicines Directive (FMD) Medicines are the most common intervention made across the NHS. It is essential that patient can have confidence in the medicines they are supplied and that systems are in place to prevent counterfeit

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU

More information

By Christoph Frick and Nicola Spiggelkötter. Creating a Master Plan for Drug Warehousing, Transportation and Distribution

By Christoph Frick and Nicola Spiggelkötter. Creating a Master Plan for Drug Warehousing, Transportation and Distribution By Christoph Frick and Nicola Spiggelkötter Creating a Master Plan for Drug Warehousing, Transportation and Distribution ISBN: 978-3-943267-93-8 Where a product trademark, registration mark, or other protected

More information

Procedure: Managing GMP Regulation Changes

Procedure: Managing GMP Regulation Changes Effective Date: TBD Procedure: Document information, authorship and approvals Author signs to confirm technical content Prepared by: Job title: Signature: Date: Subject matter expert reviewer signs to

More information

<Full Name> Quality Manual. Conforms to ISO 9001:2015. Revision Date Record of Changes Approved By

<Full Name> Quality Manual. Conforms to ISO 9001:2015. Revision Date Record of Changes Approved By Conforms to ISO 9001:2015 Revision history Revision Date Record of Changes Approved By 0.0 [Date of Issue] Initial Issue Control of hardcopy versions The digital version of this document is

More information

Annex 4. Guidance on good manufacturing practices: inspection report. Background

Annex 4. Guidance on good manufacturing practices: inspection report. Background Annex 4 Guidance on good manufacturing practices: inspection report Background The need for revision of the Guidance on good manufacturing practices: inspection report (World Health Organization (WHO)

More information

DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency

DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency Introduction to EU Regulatory system and GMP Inspection system. The Qualified Person. DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency Any views expressed may not necessarily

More information

HACCPEUROPA PUBLICATIONS ISO 22000:2005 FOOD SAFETY QUALITY MANUAL. ISO 22000:2005 Quality Manual

HACCPEUROPA PUBLICATIONS ISO 22000:2005 FOOD SAFETY QUALITY MANUAL. ISO 22000:2005 Quality Manual HACCPEUROPA PUBLICATIONS ISO 22000:2005 FOOD SAFETY QUALITY MANUAL ISO 22000:2005 Quality Manual QUALITY MANUAL ISO 22000:2005 Food Safety Management HACCPEuropa Publications 2012 Table of Contents Introduction...

More information

etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector

etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs

More information

The APIC Audit Programme Version 5, July 2017

The APIC Audit Programme Version 5, July 2017 The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification

More information

Earlsfort Centre Earlsfort Terrace Dublin 2 Ireland

Earlsfort Centre Earlsfort Terrace Dublin 2 Ireland Earlsfort Centre Earlsfort Terrace Dublin 2 Ireland GUIDANCE NOTE ON THE WHOLESALING OF MEDICINAL PRODUCTS FOR HUMAN USE IN IRELAND OCTOBER 2004 This guidance note does not purport to be the definitive

More information

Current Trends in Data Quality and Integrity Issues in Inspections and Risk Based Approach to Investigations; EU perspective

Current Trends in Data Quality and Integrity Issues in Inspections and Risk Based Approach to Investigations; EU perspective Current Trends in Data Quality and Integrity Issues in Inspections and Risk Based Approach to Investigations; EU perspective Mark Birse / Richard Andrews, MHRA Data Integrity has no relationship with product

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Medicinal Product quality, safety and efficacy Brussels, 16 August 2013 EudraLex The Rules Governing Medicinal

More information

POLYCRAFT INCORPORATED QUALITY MANUAL Quality Manual QM -10 Approval: D. Wheeler.

POLYCRAFT INCORPORATED QUALITY MANUAL Quality Manual QM -10 Approval: D. Wheeler. Polycraft, Inc. QM - 10 Title: Polycraft, Inc. Quality Manual Copy Approval: D. Wheeler This Quality Manual is the sole property of Polycraft, Inc. and intended for exclusive use by the organization. This

More information

Submission of comments on Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use (SANCO/C8/AM/an D(2010) )

Submission of comments on Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use (SANCO/C8/AM/an D(2010) ) 29/12/2011 Submission of comments on Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use (SANCO/C8/AM/an D(2010) 380358) Comments from: Name of organisation or individual

More information

Guide to Scientific and Regulatory Advice for GXP activities

Guide to Scientific and Regulatory Advice for GXP activities Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.

More information

GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE

GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 047-1 Annex 1 July 2018 GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL

More information

<1079> Good Storage and Distribution Practices

<1079> Good Storage and Distribution Practices Good Storage and Distribution Practices Desmond Hunt, Ph.D. Principal Scientific Liaison September 7, 2017 Mexico City, Mexico Good Distribution Practice Activities Suppliers Procuring, holding,

More information

Wilson-Hurd ATF Quality Manual

Wilson-Hurd ATF Quality Manual Wilson-Hurd ATF Quality Manual Wilson-Hurd Manufacturing Company Advanced Technical Facility (ATF) 311 Winton Street Wausau, WI 54403 Rev. Date: 04 May 2017 Pete Dehne Vice President, Operations Table

More information

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern

More information

QUALITY MANUAL. This document defines the requirements, processes, structure and documentation for the Teledyne DGO Quality Management System.

QUALITY MANUAL. This document defines the requirements, processes, structure and documentation for the Teledyne DGO Quality Management System. Page 1 of 13 1. PURPOSE This document defines the requirements, processes, structure and documentation for the Teledyne DGO Quality Management System. 2. SCOPE The Teledyne DGO Quality Management System

More information

The Pharmacovigilance Quality System. What is it?

The Pharmacovigilance Quality System. What is it? The Pharmacovigilance Quality System What is it? by Andy Blackman 12 November 2018 Are you starting to plan your first Marketing Authorisation Application? If yes, now is the time to start developing your

More information

Developing an Internal Quality Auditing Program

Developing an Internal Quality Auditing Program Developing an Internal Quality Auditing Program SeerPharma Pty Lt Capsig August 2009 1 Critical Success Factors Culture of Compliance Integrate quality systems and risk management principles Well defined

More information

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Computerised Systems Inspection Expectations ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Paul Moody, Inspector Slide 1 Presentation Contents Brief Introduction to the IMB Regulatory References

More information

STANDARD OPERATING PROCEDURE TEAM INSPECTIONS

STANDARD OPERATING PROCEDURE TEAM INSPECTIONS PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 031-1 Annex 29 July 2009 STANDARD OPERATING PROCEDURE TEAM INSPECTIONS PIC/S July 2009 Reproduction prohibited for

More information

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009

European Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009 European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities

More information

Green Gold Label Program

Green Gold Label Program Green Gold Label Program Introduction & scope Green Gold Label biomass are (residual) products of agricultural or forestry origin and related industries that are compliant with the relevant national requirements

More information

HACCP audit checklist

HACCP audit checklist Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal

More information

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION

(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION 21.3.2015 EN Official Journal of the European Union C 95/1 II (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Guidelines of 19 March 2015 on

More information

The APIC Audit Programme Version 3, August 2010

The APIC Audit Programme Version 3, August 2010 The APIC Audit Programme Version 3, August 2010 Table of contents 1 General 2. APIC Audit Program 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification

More information

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER 7 2016 TUUSULA FINLAND Timo Kuosmanen STERIS Finn-Aqua Timo_Kuosmanen@steris.com AUDIT TRAIL IN CRITICAL UTILITIES MONITORING CURRENT TRENDS CONTENTS BACKGROUND

More information